Waiting for a catalyst on Viking Therapeutics (VKTX) has certainly been trying.
But today the stock gained 36% on news of very positive Phase 2 obesity data for injectable VK2735, Viking Therapeutics’ dual GLP-1/GIP agonist.
Even after today’s gain, I’d note my February 28, 2004 position in my Jubak Picks Portfolio is still down 57%.
In a 33-week obesity study, drug candidate VK2735 produced up to 22% placebo-adjusted mean weight loss at the 17.5 mg once-weekly dose, with no weight-loss plateau reported at Week 33.
But it was the maintenance data that really moved the stock, in my opinion. Weight loss maintained over 12 weeks with
Every-other-week injection was Up to 97%. With once-monthly injection weight-loss maintenance was 90%.
The high level of maintenance with less-frequent dosing is strategically important because it could differentiate VK2735 from required weekly GLP-1 obesity injections from Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide. The trial results support the possibility that VK2735 could be a high-efficacy competitor in the obesity market. Maintaining most prior loss with biweekly or monthly dosing could improve adherence and provide a commercially meaningful product profile.
These were only Phase 2 results. At its July update, the company said its Phase 3 VANQUISH 1 and VANQUISH 2 subcutaneous VK2735 trials were fully enrolled and progressing, and that its oral Phase 3 program was being initiated.
At the end of the second quarter, Viking reported approximately $502 million of cash on hand.
